Barclays analyst Matt Miksic maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $278.00. The ...

Life science real estate developer Breakthrough Properties bought the three-building Muse complex at 3030, 3040 and 3050 ...

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year’s $2.68. Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...

Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...